CareDx (CDNA) Could Be 8% Overvalued On Payer Coverage And Reimbursement Hopes

CareDx (CDNA) has drawn fresh attention after recent share gains, with the stock closing at $56.49 as of 21 September 2026. Investors are weighing that move against its recent financial and return profile.

Recent trading has come with strong momentum, with CareDx showing a 16.21% 1 month share price return and a 108.22% 3 month share price return. The 1 year total shareholder return of 262.81% signals a sharp repricing of the company’s prospects and risks.

See how CareDx’s recent surge compares with other rapidly repricing healthcare names by reviewing the hand picked 37 healthcare AI stocks now capturing market attention.

Bulls see CareDx as a transplant testing leader now repriced for a stronger business mix. Bears see a sharp sentiment swing ripe for disappointment. Which story do the current valuation markers lean toward?

Most Popular Narrative: 7.9% Overvalued

CareDx closed at $56.49, while the most followed narrative pegs fair value closer to $52.33, suggesting the recent run has moved ahead of that fair value line. That view leans heavily on how reimbursement, digital health expansion, and cost discipline shape cash flows under a 7.4% discount rate.

Significant progress in payer coverage, including millions of new covered lives, expanded in network status, and the implementation of a unique CPT code for AlloSure, indicates a catalyst for sustained increases in ASP (average selling price) and recurring revenue streams, which can directly enhance future profitability and margin expansion.

See why 4 investors see CareDx as 8% overvalued.

Result: Fair Value of $52.33 (OVERVALUED)

Still, the Medicare reimbursement backdrop and any stumble in integrating Naveris could quickly undermine the fair value assumptions that currently support CareDx.

Find out about the key risks to this CareDx narrative.

Another View On CareDx’s Valuation

DCF math tells a very different story. Our DCF model suggests CareDx is trading below an estimated future cash flow value of $91.62, which points to the stock being undervalued rather than 7.9% overvalued. Which signal do you trust more: the cash flows or the narrative fair value line?

Look into how the SWS DCF model arrives at its fair value.

Next Steps

CareDx inspires both optimism and caution right now, so your perspective may be more important than any single model. Consider the latest information and weigh both sides of the story by reviewing the company’s 2 key rewards and 4 important warning signs

Looking for more CareDx sized investment ideas?

If you stop at CareDx, you may miss other opportunities that fit your style, so put the Simply Wall Street Screener to work for you.

• Target quality at a discount by scanning the market for 29 high quality undervalued stocks that combine strong fundamentals with prices that sit below their estimated worth.
• Prioritise resilience by focusing on 30 resilient stocks with low risk scores that show steadier risk scores and can help balance out more volatile positions.
• Hunt for tomorrow's leaders early by reviewing 16 high quality undiscovered gems that have solid business metrics but limited market attention so far.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com